metricas
covid
Buscar en
Revista de Psiquiatría y Salud Mental (English Edition)
Toda la web
Inicio Revista de Psiquiatría y Salud Mental (English Edition) Secondary effects of antipsychotic treatment in naïve or quasi-naïve children ...
Información de la revista
Vol. 5. Núm. 4.
Páginas 217-228 (octubre - diciembre 2012)
Visitas
4401
Vol. 5. Núm. 4.
Páginas 217-228 (octubre - diciembre 2012)
Original article
Acceso a texto completo
Secondary effects of antipsychotic treatment in naïve or quasi-naïve children and adolescents: Design of a follow-up protocol and baseline results
Efectos secundarios del tratamiento antipsicótico en niños y adolescentes naïve o quasi-naïve: diseño de un protocolo de seguimiento y resultados basales
Visitas
4401
Jessica Merchán-Naranjoa,
Autor para correspondencia
jmerchan@iisgm.com

Corresponding author.
, Cecilia Tapiaa, Concha Bailóna, Carmen Morenoa, Inmaculada Baezab, Rosa Calvo-Escalonab, Astrid Morerb, Carmen Martínez-Cantareroc, Patricia Andrés Nestaresc, José Ángel Aldad, Daniel Muñozd, Celso Arangoa
a Sección de Psiquiatría del Niño y el Adolescente, Departamento de Psiquiatría, CIBERSAM, Instituto de Investigación Sanitaria Gregorio Marañón, IISGM, Hospital General Universitario Gregorio Marañón, Madrid, Spain
b Servicio de Psiquiatría y Psicología infanto-juvenil, Hospital Clínic i Universitari de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Barcelona, Spain
c Sección de Psiquiatría y Psicología, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
d Servicio de Psiquiatría y Psicología infanto-juvenil, Hospital Sant Joan de Déu, CIBERSAM, Barcelona, Spain
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (5)
Table 1. Patients included by participating centre.
Table 2. Baseline sample descriptors (n=266).
Table 3. Baseline biochemical and haematological results.
Table 4. Baseline scores for the UKU (Udvalg für Kliniske Undersogelser) scale.
Table 5. Baseline scores for the MPRC-IMS (Maryland Psychiatry Research Center Involuntary Movement Scale).
Mostrar másMostrar menos
Abstract
Introduction

The prescribing of anti-psychotic drugs has become a normal clinical practice.

Methods

This article presents a longitudinal, multicentre 12-months-long study conducted on 266 children and adolescents who were prescribed a first or second generation antipsychotic drug for the first time, and the baseline results of the study. The follow-up protocol had its purpose to detect the possible appearance of metabolic, cardiological, and motor changes.

Results

When the presence of side effects was evaluated using the UKU (clinical side-effects scale) statistically significant differences were found between naïve (patients who had never taken an anti-psychotic drug) and quasi-naïve patients (those who have taken anti-psychotic drugs for a period of less than 30 days), with a greater number of the latter showing symptoms of: anxiety/laxity/tiredness (P=0.0049), drowsiness/sedation (P<0.001), increase in dream duration (P<0.001), increase in dreams (P=0.0199), emotional indifference (P=0.0194), hypokinesia/akinesia (P=0.0224), paresthesias (P=0.0049), accommodation disorder (P=0.0254), increase in salivation (P<0.001), polyuria/polydipsia (P=0.0076), increase in sweating (P=0.0076), increase in sexual desire (P=0.0117), decrease in sexual desire (P=0.0053), tension headaches (P=0.0405). When the presence of extrapyramidal symptoms was assessed using the MPRC-IMS (Maryland Psychiatry Research Center-Involuntary Movement Scale), it was observed that the quasi-naïve patients had a statistically higher number of dyskinesia (P=0.002), Parkinsonism (P=0.0004) and akathisia (P=0.0437) symptoms compared to the naïve patients.

Conclusions

These results show that, in the childhood–adolescent population, the presence of secondary effects begins to be observed from the first dose of the antipsychotic drug.

Keywords:
Antipsychotic
Paediatric population
Extrapyramidal
Metabolic
Cardiology
Resumen
Introducción

La prescripción de fármacos antipsicóticos en niños y adolescentes se ha convertido en una práctica habitual.

Métodos

Este artículo presenta el diseño de un estudio multicéntrico longitudinal a 12 meses con 266 niños y adolescentes a los que se les prescribió por primera vez un antipsicótico de primera o segunda generación y los resultados basales del estudio. El protocolo de seguimiento tuvo como finalidad detectar la posible aparición de cambios metabólicos, cardiológicos y motores.

Resultados

Cuando se valoró la presencia de efectos secundarios a través de la UKU (Udvalg für Kliniske Undersogelser) se encontraron diferencias estadísticamente significativas entre pacientes naïve (pacientes incluidos que nunca habían tomado antipsicótico) y quasi-naïve (aquellos que habían tomado antipsicóticos durante un periodo inferior a 30 días), mostrando un mayor número de estos últimos síntomas de: ansiedad/laxitud/fatigabilidad (p=0,0049), somnolencia/sedación (p<0,001), aumento duración sueños (p<0,001), aumento de sueños (p=0,0199), indiferencia emocional (p=0,0194), hipocinesia/acinesia (p=0,0224), parestesias (p=0,0049), trastorno de acomodación (p=0,0254), aumento de la salivación (p<0,001), poliuria/polidipsia (p=0,0076), aumento de la sudoración (p=0,0076), aumento del deseo sexual (p=0,0117), disminución del deseo sexual (p=0,0053), cefaleas tensionales (p=0,0405). Cuando se valoró la presencia de síntomas extrapiramidales con la MPRC-IMS (Maryland Psychiatry Research Center-Involuntary Movements Scale) se observó que los pacientes quasi-naïve presentaron un número estadísticamente superior de síntomas de discinesia (p=0,002), parkinsonismo (p=0,0004) y acatisia (p=0,0437) con respecto a los naïve.

Conclusiones

Estos resultados ponen de manifiesto que en población infanto-juvenil, la presencia de efectos secundarios se comienza a observar ya desde el inicio de la toma de fármacos antipsicóticos.

Palabras clave:
Antipsicótico
Población infanto-juvenil
Extrapiramidal
Metabólico
Cardiológico
Texto completo
Introduction

In the last few years, the prescription of antipsychotic drugs has increased, both for psychotic disorders as well as for other mental disorders in children and adolescents.1–5 Despite the limited indications for these treatments in this age group,6,7 this practice is becoming a habit in psychiatric clinical practice, especially in the case of the second generation [atypical] antipsychotics (SGA).8–11

Studies on the prevalence of use of antipsychotics in the paediatric population have shown a progressive decrease in the use of first generation antipsychotic (FGA) drugs,12 accompanied by a significant increase in SGA prescriptions.2,11 A UK study found a rise in SGA prescriptions in the child–adolescent population of almost 60 times (jumping from 0.01 users per 1000 patients in 1994 to 0.61 users per 1000 patients in 2005).12 Likewise, another USA study found an increase of 160% in the years from 1990 to 2000.7 This rise has been observed not only in prescriptions, but also in the period of exposure to these drugs (from 0.8 months in 1998–1999 to 1.6 months in 2001).13

The data to date have shown that the SGA as a group having fewer adverse neurological motor effects than the FGA in children and adolescents5,14; in contrast, most FGA are associated with an increase in the risk of metabolic complication (obesity, type II diabetes mellitus, dyslipidemia and cardiovascular disorders).4,5,14–17

The current literature reflects a relevant aspect: the stability over time of the metabolic side effects of the various antipsychotic drugs. In a study with adolescents and adults, there was a weight increase, greater in the olanzapine group (olanzapine>risperidone>haloperidol) after 3 months’ treatment with antipsychotics (olanzapine, risperidone and haloperidol).18 In contrast, when the weight gains were compared after 12 months of treatment, there were no significant differences among the 3 groups. In a study19 performed on adolescents with a first psychotic episode treated with olanzapine or quetiapine, the group treated with olanzapine had a greater weight gain after 6 months of follow-up than the group treated with quetiapine (olanzapine Δ 15.5kg; quetiapine Δ 5.5kg); the body mass index (BMI) showed similar results (olanzapine Δ 5.4 points; quetiapine Δ 1.8 points). Another study16 with children and adolescents treated with olanzapine, quetiapine or risperidone found a significant increase in weight in 50% of the sample at 6 months’ follow-up and significantly significant increases in the BMI z-score, in both the olanzapine and the risperidone groups. Similar data were obtained in another 12-month longitudinal study20 with a naïve child–adolescent population. The same effect on the BMI z-score in that study in the 3 treatment groups (olanzapine, quetiapine and risperidone) at 12 months’ follow-up; this increase was significantly greater in the first 6 months of treatment.

When dealing with metabolic side effects in the paediatric population, it is important to remember that psychotic disorders represent a greater risk per se associated to the appearance of metabolic complications, as backed by studies on adults.21 In a recent study22 with children and adolescents, there was a greater incidence of overweight associated with obesity complications (hypertension, dyslipidemia and hyperglycaemia) linked to SGA treatment in naïve adolescents diagnosed with bipolar disorder than in subjects with any other diagnosis. Nevertheless, the weight gain after 3 months of SGA treatment was 5.5kg in this same study, with no differences by diagnosis. This indicates that the SGA affect the metabolic parameters of minors negatively, whatever pathology they present.

Bearing in mind that the paediatric population is more vulnerable than the adult one to side effects from antipsychotic drugs (and that it is also more sensitive to the negative impact these effects have on body image or self-esteem), the need to increase research that involves these aspects is evident.

Despite the studies carried out, there are still important data to ascertain. The majority of the research is performed with patients who have taken antipsychotics, during more or less long periods before the patients are included in the studies. This fact introduces factors of confusion in data interpretation. In addition, the studies published to date include short follow-up periods16,19,23; this constitutes a limitation in determining if the side effects become stable, improve or disappear—or if, in contrast, they continue increasing throughout the entire exposure period.

Based on the data indicated, it seems necessary to expand and explore the causal relationship between the appearance of adverse side effects and the administration of antipsychotic drugs in the paediatric population.

Our study aimed to provide the protocol for a study whose goal was to measure the possible appearance of metabolic, heart and motor changes throughout the 12 months of follow-up, in children and adolescents who had received first and second generation antipsychotics for the first time. The baseline study data were also included. Our study hypothesis was that the patients who were already taking antipsychotic treatment in the baseline visit would present a greater number of side effects characteristic of the antipsychotic medication than those that, when included in the study, were patients who had not taken antipsychotics previously.

Materials and methodsSample

This was a naturalistic, observational, longitudinal multicentre study in which 4 Spanish hospitals participated: Hospital General Universitario Gregorio Marañón (HGUGM) and Hospital Infantil Universitario Niño Jesús in Madrid, and Hospital Clínic and Hospital Sant Joan de Déu in Barcelona. The subjects were patients treated in out-patient consultations and in-hospital patients. Recruitment was carried out between May 2005 and February 2009.

The criteria for inclusion were: (1) children and adolescents between 4 and 17 years of age; (2) any psychiatric diagnosis based on the diagnostic criteria of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)24; (3) medical prescription of antipsychotic medication, both first and second generation drugs; and (4) a period of antipsychotic drug taking less than 30 days at the moment of including the patient in the study.

The patients included in the study who had never taken antipsychotics were classified as naïve, while patients who had taken antipsychotics for less than 30 days when they were included in the study were classified as quasi-naïve.

Ethical considerations

This study was approved by the Clinical Ethics and Research Committee at each of the hospitals that collaborated in recruiting. The parents/legal guardians of the participants gave written informed consent and the minors agreed, guaranteeing data confidentiality. We offered the participants and/or their legal guardians the possibility of raising any questions deemed necessary, as well as the liberty to abandon the study whenever they wished.

Study follow-up

The study follow-up period was established as 1 year, with a total of 5 visits (baseline, 1 month, 3 months, 6 months and 12 months). Each of the patients was given appointments through telephone calls. The appointment for the corresponding visit could not exceed the window established for the study (a third of the inter-visit period). Specifically, the windows for the 1, 3, 6 and 12-month visits were set as: ±10, ±20, ±30 and ±60 days, respectively.

In the baseline visit, we used a structured interview, with the patients and their parents or legal representatives. The data collected were demographic data, the patient's personal medical history, family medical-psychiatric history and use of toxic substances, as well as the past history of dystonias and extrapyramidal symptoms associated with any medications. All this information, except for the family medical-psychiatric antecedents, was collected in the rest of the visits as well to control for possible changes. The diagnoses were performed by psychiatrists trained for the child-juvenile population, based on the DSM-IV diagnostic criteria.24 Personal medical information collected was as follows: recurrent streptococcal pharyngitis, rheumatic fever, traumatic brain injury (TBI) with loss of consciousness, blood transfusion, encephalitis/meningitis, convulsions/epilepsy, heart diseases, dyslipidemia, diabetes mellitus, overweight/obesity, allergies/asthma, arthritis, foetal exposure to drugs/alcohol, current psychosis, past psychosis, prior electroconvulsive therapy, lack of medical antecedents: always healthy, computed axial tomography (CAT)/magnetic resonance (MR) (with findings) and other illnesses (specifying which).

Family medical history data collected was recurrent streptococcal pharyngitis, rheumatic fever, Huntington's disease, Parkinson's disease, Gilles de la Tourette syndrome, diabetes mellitus, dyslipidemia, overweight/obesity, heart diseases, affective disorders, psychotic disorders and other family illnesses (specifying which). In all these cases, the relative affected and whether or not the pathology was present were recorded.

When the study ended, a finalisation sheet, in which the date on which the patient finished participating in the study was recorded, was filled out. If the interruption was early, we indicated the reason (lost to follow-up, lost to follow-up but continued with medication, symptom remission, patient's lack of collaboration, persistent poor compliance, intolerance, lack of clinical response/intolerance, admission to a psychiatric hospital, death (specifying the cause) and others (specifying the cause)).

Biological measurements

Height, weight, abdominal perimeter, blood sample (including haemogram and biochemical and hormonal parameters), blood pressure and electrocardiogram (ECG) for each patient were collected by the nursing team. This protocol was applied in all the study follow-up visits, apart from the visit on the month in which all the tests except for the ECG and blood sample were performed.

The biochemical parameters obtained were fasting glucose (prior food 9h before the extraction), triglycerides, total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL), glycosylated haemoglobin A1c (HbA1c) and homocisteine. Blood glucose, total cholesterol, HDL, LDL and triglycerides were determined by enzymatic procedures using the Boehringer Mannheim/Hitachi 714 automated chemistry analyser (Boehringer Mannheim Diagnostics, Inc., Indianapolis, Ind.): (1) glucose test (Roche Diagnostics, Mannheim, Germany); (2) cholesterol test (Boehringer Mannheim Diagnostics, Indianapolis, Ind.). Adams HA-8186 (Menarini, Zaventem, Belgium) high performance liquid chromatography (HPLC) was used to analyse HbA1c. In addition, the Hospital Clínic obtained the homocisteine values through fluorescence immunoassay (Abbot: AXSYM). The laboratory at each of the hospitals classified the data obtained taking into consideration the normality criteria (maximum and minimum) established for each of the parameters. The hormonal parameters measured were thyrotropin or thyroid stimulating hormone (TSH), free thyroxine (FT4), adiponectin, leptin and ghrelin. Both TSH and FT4 were measured using radioimmunoassay (Diagnostic Product Corporation, Los Angeles, CA). Adiponectin and leptin values were determined only at the HGUGM in Madrid and the Hospital Clínic in Barcelona. In the HGUGM, the adiponectin figures were obtained in duplicate using enzyme-linked immunosorbent assay (ELISA) (BioVendor, ref: RD195023100) and those of leptin using ELISA (BioVendor, ref: RD191001100). In the Hospital Clínic in Barcelona, the leptin and adiponectin were obtained by radioimmunoassay (Linco Research, St. Charles, MO). The Hospital Clínic also obtained by ghrelin measurements by radioimmunoassay (Ghrelin-Total RIA Kit; Linco Research).

Weight and height were always measured with the same sliding-weight scale at each hospital. The scales utilised by the HGUGM, Clínic, HNJ and HSJD hospitals were the Asimed S.A., SosPanduri, Soehnle, Vogel & Halke Hamburg Model 701 and SECA 220, respectively. Weight was recorded in kilograms (kg) and height in metres. From these data, the BMI was calculated, being understood as: weight in kg/height in metres squared [kg/m2]. Considering that the age range for study inclusion was very wide (4–17 years) and that the children and adolescents were still growing, we also calculated the BMI z-score del BMI, in agreement with standard Spanish tables.25

For the ECG, the patient was lying down face up, using the same electrocardiograph at each hospital. The electrocardiographs used at the HGUGM, Clínic, HNJ and HSJD hospitals were: Delta 1Plus Digital Electrocardiogram, Siemens Scard 440, Delta 1Plus Digital Electrocardiogram and Bio-Tek (Lionheart-1), respectively. The parameters obtained with the ECG were the ventricular rhythm (beats per minute, bpm), PR (ms), QRS (ms), and QTc (ms).

The abdominal perimeter was measured at all the centres based on the protocol that the Spanish Society for Obesity Study (SEEDO) used. The procedure was performed with a flexible, metrically graduated measuring tape, with the subject in a standing position, unclothed and relaxed. The upper border of the iliac crest was located and the measuring tape was put around the waist above this point, parallel to the floor, making sure that the tape was snug but without compressing the skin. The reading was taken at the end of a normal exhalation. The abdominal perimeter percentiles of all the patients were found, based on the Spanish tables for children and adolescents.26

Blood pressure was taken with the patient lying down, using the same sphygmomanometer at each hospital; the devices used at the HGUGM, Clínic, HNJ and HSJD hospitals were: OMRON M 6 (HEM-700-1E) digital blood pressure monitor; OMRON M 6 (HEM-700-1E), Vital Signs Monitor 300 series (Welch Allyn) P/No. 810-1707-00 and HARTMANN TENSOVAL monitor, respectively. Blood pressure was assessed for each patient using the percentiles proposed by the International Task Force for BP.27

Treatment

In each of the visits, we recorded in detail the antipsychotic drug prescribed for the patient, noting both changes to the antipsychotic and changes in dose. Likewise, all the concomitant drugs received by patient (antidepressants, stimulants, benzodiazepines, mood stabilisers and anticholinergics). In each visit, the dose of the antipsychotics was converted to chlorpromazine equivalents.28 For all of the patients, we recorded the daily intake dose of antipsychotics in each visit; later, the dose accumulated during the period from one visit to the other (dose×days of exposure) was calculated.

In the Madrid HGUGM and in the Barcelona Hospital Clínic, compliance to antipsychotic treatment was determined by measuring the plasma levels of the antipsychotic using HPLC (Alliance 2695). The rest of the centres based this determination on the psychiatrists’ criteria, because this technique was unavailable there. Study continuation criteria were that the patients had appropriate adherence to treatment and were taking for 12 months.

Use of toxic substances

Recording the use of toxic substances was carried out through an interview designed for the study, in which we asked the patients about their use of toxic substances with respect to tobacco, alcohol, cannabis, cocaine, opiates, amphetamines and derivatives, lysergic acid diethylamide (LSD), inhalants and other substances (specifying which). We always recorded if there had been use or not; if there had been, we also noted the patient's use pattern (daily, at the weekend, occasionally). In the case of tobacco use, the number of cigarettes a day was also noted.

Clinical scales

In each of the visits, the patients’ pubertal development was assessed. Likewise, we assessed the presence of side effects and involuntary movements provoked by the antipsychotic drugs.

Assessment of pubertal development

To assess pubertal development, the tables designed by Tanner29,30 were used. These divide breast and public and genital hair development into 5 levels; they make an objective assessment of pubertal progression possible and are used universally. The patients themselves were the ones who indicated the level in which they were, except in the case of the smaller children, in which the parents or guardians/legal representatives that accompanied them provided this information.

Assessment of side effects from the antipsychotic drugs

To assess the presence of side effects, we used the UKU (Udvalg für Kliniske Undersogelser) scale.31 This is an over-all measurement of the adverse psychological and physical effects that use of psychotropic drugs produces; it is constituted by 48 items grouped as follows: adverse psychological, neurological and autonomic effects and other symptoms (dermatological, photosensitivity, weight gain/loss, hormonal, sexual, headaches physical/psychological dependence on the drug). The items are scored from 0 to 3 points to determine the severity of the symptom: 0: indicates lack or doubtful presence of the symptom; 1: slight; 2: moderate; and 3: severe; 9: not assessed. The possible causal relationship of the drug with the symptoms was assessed by from 0 to 2 points to these items (0: indicates improbable; 1: possible; and 2: probable).

The UKU scale was administered using a semi-structured interview given by trained psychologists and psychiatrists.

Assessment of involuntary movements

To assess the presence of involuntary movements, we used the MPRC-IMS.32 This consists of 28 items structured topographically into the following corporal areas: tongue, perioral region, eyes and periorbital region, face and jaw, fingers and wrists, arms and elbows, neck, shoulders and head, thighs and knees, lower legs and feet, arm movement and tension, gait, waist and respiration.

These items measured the presence of 2 extrapyramidal symptoms (dyskinesia and parkinsonism) linked with the antipsychotic drug use. Each item was scored from 0 to 7 points (0–1: none; 2–3: slight; 4–5: moderate; 6–7: severe).

The overall assessments of dyskinesia and parkinsonism were obtained by adding up the scores of the 14 items that constituted each of the subscales. The MPRC-IMS makes an overall assessment of akathisia possible through subjective observation by the psychiatrist/psychologist throughout the examination.

To administer the MPRC-IMS, one of the psychiatrists was trained by the authors of the scale, obtaining interclass correlation coefficients (ICC) of 0.8–0.9 in the various items constituting the scale. Afterwards, the rest of the psychologists and psychiatrists that participated in the assessment passed through the same training, requiring a minimum ICC of 0.8 for each item for them to be able to administer the scale.

Statistical analysis

Descriptive or frequency analyses were performed depending on whether the variables were continuous or discrete, respectively. The presence of statistically significant differences between naïve and quasi-naïve groups at baseline level in the variables of age, sex, race and diagnosis was analysed; to do so, Student's t-test was used for the age variable and χ2 for the rest (sex, race and diagnosis). We compared the presence of side effects among the naïve and quasi-naïve groups, controlling by diagnosis, using a Cochran–Mantel–Haenszel test. For these analyses, we used the statistical package SPSS 18.0 for Windows. The statistical tests were carried out as 2-tailed tests and statistical significance was defined as P<0.05.

Results

The number of patients included in the study was 266 children and adolescents (Table 1). The descriptive sample analysis results are presented in Table 2. From the total of the sample analysed, 72.9% (n=194) were recruited during hospital admission. The rest came from external psychiatric consultations.

Table 1.

Patients included by participating centre.

Participating centres  No. of patients 
Hospital General Universitario Gregorio Marañón (Madrid)  86 
Hospital Clínic (Barcelona)  80 
Hospital Infantil Universitario Niño Jesús (Madrid)  55 
Hospital Sant Joan de Déu (Barcelona)  45 
Total  266 
Table 2.

Baseline sample descriptors (n=266).

Sex
Males no. (%)  148 (55.6) 
Age
Mean±SD  14.4±2.91 
Race
Caucasian no. (%)  237 (89.1) 
Diagnosis (DSM-IV criteria) no. (%)
Bipolar disorder  39 (14.7) 
Unspecified psychosis  38 (14.3) 
Behaviour disorder  38 (14.3) 
Eating disorder  30 (11.3) 
Brief psychosis/Schizo-phreniform disorder  25 (9.4) 
Schizophrenia/Schizo-affective disorder  17 (6.4) 
Transient tic disorder  13 (4.9) 
Depression with psychotic symptoms  13 (4.9) 
Affective-depressive disorder without psychotic symptoms  13 (4.9) 
Attention hyperactivity deficit disorder  9 (3.3) 
Generalised development disorder  9 (3.4) 
Adaptive disorder  9 (3.3) 
Substance-related disorder  6 (2.3) 
Obsessive–compulsive disorder  4 (1.5) 
Yes psychosis no. (%)  150 (43.6) 
Naïve patients no. (%)  131 (49.2) 
Period of previous antipsychotic use in quasi-naïve patients (days)  5.32±7.56 
Mean daily dose±SD, mg/d (chlorpromazine equivalent)  105.39±170.13 
Concomitant treatment
Antidepressants no. (%)  51 (19.2) 
Benzodiazepines no. (%)  76 (28.6) 
Mood stabilisers (lithium/antiepileptic) no. (%)  36 (13.5) 
Stimulants no. (%)  8 (3) 
Use of toxic substances
Tobacco no. (%)  93 (35) 
Alcohol no. (%)  79 (29.7) 
Cannabis no. (%)  81 (30.68) 
Amphetamines  6 (2.3) 
LSD  2 (0.8) 
Inhalants  1 (0.4) 

LSD: lysergic diethylamide acid; naïve: patients who had not taken any antipsychotic drugs before being included in the study; quasi-naïve: patients who had taken antipsychotics for a period of less than 30 days before being included in the study; SD: standard deviation.

The results of analysing the personal medical histories recorded in the baseline visit of all of the patients were as follows: 43.6% with no medical antecedents, always healthy; 38% current psychosis; 24.1% allergies/asthma; 19.5% having received a CAT/MR at some time; 11.3% recurrent streptococcal pharyngitis; 8.3% TBI with loss of consciousness; 7.9% overweight/obesity; 7.1% past psychosis; 4.5% convulsions/epilepsy; 3% encephalitis/meningitis; 2.6% rheumatic fever; 2.6% heart diseases; 1.1% blood transfusion; 0.8% dyslipidemia; 0.8% foetal exposure to drugs/alcohol; 0.4% diabetes mellitus; 0.4% arthritis.

The family medical antecedents recorded at the baseline visits of all the patients (expressed in percentages) include at least 1 relative with the following pathologies: 42.49% affective disorders; 24.43% heart diseases; 23.68% diabetes; 22.18% overweight/obesity; 15.41% psychotic disorders; 12.78% recurrent streptococcal pharyngitis; 4.14% Parkinson's; 3.53% dyslipidemia; 3.38% rheumatic fever; 1.5% Tourette syndrome; and 0.36% Huntington's disease.

Biological measurements

The mean and standard deviation (SD) value of the baseline sample BMI was 20.22±3.59kg/m2, and that of the abdominal perimeter was 74.61±10.71cm. In the case of blood pressure, the mean systolic blood pressure (SBP) at baseline level was 113.43±16.31mmHg, while the diastolic (DBP) was 65.19±12.00mmHg.

Table 3 presents the means and SD of the biochemical and haematological data from the blood extractions.

Table 3.

Baseline biochemical and haematological results.

  Mean±SD  Normal range 
Biochemical analyses
Glucose  82.98±10.99  60–100mg/dL 
Total cholesterol  156.74±36.29  <200mg/dL 
HDL  52.98±13.18  40–60mg/dL 
LDL  88.38±25.60  <130mg/dL 
Triglycerides  70.22±39.75  50–150mg/dL 
HbA1c  4.72±0.57  4.0–6.0% 
Haematological
Red blood cells  4.79±0.46  4.60–5.70E6/μL 
Haemoglobin  14.06±1.40  13.0–17.5g/dL 
Haematocrit  41.33±3.96 
Leucocytes  6.96±1.760  E3/μL 
Platelets  263.03±65.12  140–400E3/μL 
Hormones
TSH  2.18±1.95  0.5–4.5U/ml 
FT4  1.16±0.35  0.6–1.4ng/dL 

FT4: free thyroxine; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation; TSH: thyroid stimulating hormone.

Baseline leptin was collected by the HGUGM and Hospital Clínic in 122 patients, whose mean and SD was 9.91±12.92ng/mL; for adiponectin in 101 patients at these hospitals, the mean and SD was 11.43±4.64μg/mL. The baseline ghrelin and homocisteine were collected by the Hospital Clínic in 35 and 61 patients, respectively. The means and SD obtained for both parameters were 1095.94±408.15pg/mL in the case of ghrelin and 9.7±5.68μmol/l for homocisteine. Six visits by 6 patients, in which the absence of plasma antipsychotic levels was shown, were eliminated.

Treatment

At the commencement of the study, 49.2% (n=131) were antipsychotic-naïve patients. The rest of the patients (50.8%), called quasi-naïve, received treatment with first generation (haloperidol=3, pimozide=1 and chlorpromazine=3) or second generation antipsychotics (risperidone=79, olanzapine=29, quetiapine=19 and aripiprazole=1). We measured the plasma levels of antipsychotics in 87 children and adolescents (32.7%) to check whether they had good adherence to the antipsychotic treatment prescribed, which all the patients analysed did. In the group of quasi-naïve patients, the mean number of days of exposure to antipsychotics before study inclusion was less than 6 days (Table 2). With a mean dose of chlorpromazine equivalents of the second antipsychotic prescribed of 361.59±265.87mg; 2.3% of the patients received combined treatment using 2 antipsychotics.

At baseline level, there were no statistically significant differences found between the naïve and quasi-naïve groups in the variables of age (t: 1.342; P=0.181), sex (χ2: 0.048; P=0.827) and race (χ2: 5.157; P=0.524). However, there was such a difference in diagnosis (χ2: 24.845; P=0.036), with there being a greater number of patients with a psychosis diagnosis in the quasi-naïve group. No significant differences were detected between both groups in weight, BMI and the SBP or DBP. In the analytical parameters, the only differences found were in prolactin (naïve group, 19.8, SD 13.1, vs quasi-naïve group, 37.7, SD 23.8; t=6.8, P<0.001).

The psychotropic drugs administered as concomitant treatment were antidepressants, mood stabilisers (lithium and antiepileptics), benzodiazepines and stimulants (Table 2).

Use of toxic substances

As for the use of toxic substances, 35% (n=93) used tobacco at the moment of the baseline visit; the mean was 4.46 cigarettes/day and the most frequent use pattern was that of the weekend (n=44; 16.5%). The mean period of use before the baseline visit was 6.48±12.6 months.

The use of the rest of toxic substances recorded was as follows: cannabis, 30.68%, with the most frequent use pattern being daily use (16.66%); cocaine, 6.8%, with occasional being the most frequent use pattern (4.1%); amphetamines, 2.3%; LSD, 0.8%; and inhalants, 0.4%. The last 3 toxic substances (amphetamines, LSD and inhalants) were used with an occasional pattern. No patient indicated use of opiates.

Clinical scalesAssessment of the side effects from the antipsychotic drugs

Table 4 presents the baseline results in the UKU scale for all the patients who obtained a score of at least slight in the symptoms assessed. For greater detail, analyses were performed on both the complete sample and differentiating between naïve and quasi-naïve patients controlled by baseline diagnosis.

Table 4.

Baseline scores for the UKU (Udvalg für Kliniske Undersogelser) scale.

Areas  Symptoms  Total sampleNo. (%)  Naïve patientsNo. (%)  Quasi-naïve patientsNo. (%)  CMH  P 
Psychological
  Concentration difficulties  169 (63.5)  83 (63.4)  86 (63.7)  0.3392  0.5603 
  Anxiety/laxity/fatigability  107 (40.2)  40 (30.5)  67 (49.6)  7.9136  0.0049 
  Somnolence/sedation  94 (35.3)  30 (22.9)  64 (47.4)  13.7952  <0.001 
  Alterations in memory  79 (29.7)  36 (27.5)  43 (31.9)  0.4782  0.4892 
  Depression  76 (28.6)  31 (23.7)  45 (33.3)  1.3888  0.2386 
  Stress/worry  96 (36.1)  49 (37.4)  47 (34.8)  0.2262  0.6344 
  Increase in sleep duration  62 (23.3)  17 (13.0)  45 (33.3)  11.7567  <0.001 
  Decrease in sleep duration  33 (12.4)  19 (14.5)  14 (10.4)  1.0098  0.3149 
  Increased sleeping  20 (7.5)  6 (4.6)  14 (10.4)  5.4231  0.0199 
  Emotional indifference  26 (9.8)  8 (6.1)  18 (13.3)  5.4685  0.0194 
Neurological
  Dystonia  9 (3.4)  2 (1.5)  7 (5.2)  1.3607  0.2434 
  Rigidity  27 (10.2)  9 (6.9)  18 (13.3)  2.2696  0.1319 
  Hypokinesia/akinesia  33 (12.4)  9 (6.9)  24 (17.8)  5.215  0.0224 
  Hyperkinesia  20 (7.5)  14 (10.7)  6 (4.4)  3.4205  0.0644 
  Tremor  41 (15.4)  16 (12.2)  25 (18.5)  1.6567  0.198 
  Akathisia  8 (3.0)  2 (1.5)  6 (4.4)  0.6629  0.4156 
  Epileptic convulsions  2 (0.8)  1 (0.8)  1 (0.7)  0.0424  0.8369 
  Paresthesias  14 (5.3)  2 (1.5)  12 (8.9)  7.9204  0.0049 
Autonomic
  Accommodation disorders  21 (7.9)  6 (4.6)  15 (11.1)  4.9972  0.0254 
  Increased salivation  23 (8.6)  2 (1.5)  21 (15.6)  13.1517  <0.001 
  Decreased salivation  25 (9.4)  9 (6.9)  16 (11.9)  1.5457  0.2138 
  Nausea/Vomiting  20 (7.5)  5 (3.8)  15 (11.1)  2.2405  0.1344 
  Diarrhoea  9 (3.4)  3 (2.3)  6 (4.4)  1.2638  0.2609 
  Constipation  33 (12.4)  10 (7.6)  23 (17.0)  1.2489  0.2638 
  Urination alterations  4 (1.5)  2 (1.5)  2 (1.5)  0.0241  0.8765 
  Polyuria/polydipsia  22 (8.3)  5 (3.8)  17 (12.6)  7.1148  0.0076 
  Orthostatic vertigo  21 (7.9)  8 (6.1)  13 (9.6)  1.1492  0.2837 
  Palpitations/tachycardia  30 (11.3)  10 (7.6)  20 (14.8)  2.6455  0.1038 
  Increased perspiration  21 (7.9)  5 (3.8)  16 (11.9)  7.119  0.0076 
Others
  Rash
  Morbilliform  0 (0)  0 (0)  0 (0)  NA  NA 
  Petechial  0 (0)  0 (0)  0 (0)  NA  NA 
  Urticarial  3 (1.1)  1 (0.8)  2 (1.5)  0.0435  0.8348 
  Psoriatic  1 (0.4)  1 (0.8)  0 (0)  0.8095  0.3683 
  Unclassifiable  1 (0.4)  0 (0)  1 (0.7)  1.3125  0.2519 
  Pruritus  7 (2.6)  2 (1.5)  5 (3.7)  1.6202  0.2031 
  Photosensitivity  6 (2.3)  1 (0.8)  5 (3.7)  1.3892  0.2385 
  Increased pigmentation  1 (0.4)  0 (0)  1 (0.7)  0.4444  0.505 
  Weight gain  37 (13.9)  18 (3.7)  19 (14.1)  0.4174  0.5183 
  Weight loss  8 (3.0)  3 (2.3)  5 (3.7)  0.1356  0.7127 
  Menorrhagia  2 (0.8)  0 (0)  2 (1.5)  2.3731  0.1234 
  Amenorrhea  8 (3.0)  3 (2.3)  5 (3.7)  0.1495  0.699 
  Galactorrhea  1 (0.4)  0 (0)  1 (0.7)  0.8235  0.3642 
  Gynaecomastia  3 (1.1)  0 (0)  3 (2.2)  3.0699  0.0798 
  Increased sexual desire  8 (3.0)  0 (0)  8 (5.9)  6.3486  0.0117 
  Decreased sexual desire  8 (3.0)  0 (0)  8 (5.9)  7.7773  0.0053 
  Erectile dysfunction  0 (0)  0 (0)  0 (0)  NA  NA 
  Ejaculatory dysfunction  3 (1.1)  1 (0.8)  2 (1.5)  0.3496  0.5543 
  Orgasmic dysfunction  2 (0.8)  2 (1.5)  0 (0)  0.8981  0.3433 
  Vaginal lubrication  1 (0.4)  0 (0)  1 (0.7)  1.5  0.2207 
  Headaches
  Tension  33 (12.4)  8 (6.1)  25 (18.5)  4.1967  0.0405 
  Migrainous  7 (2.6)  2 (1.5)  5 (3.7)  1.0757  0.2997 
  Other forms  6 (2.3)  1 (0.8)  5 (3.7)  02/01/1900  0.1365 
  Physical dependence  0 (0)  0 (0)  0 (0)  NA  NA 
  Psychological dependence  2 (0.8)  1 (0.8)  1 (0.7)  0.0076  0.9305 

CMH: Cochran–Mantel–Haenszel; NA: not applicable; naïve: patients who had not taken any antipsychotic drugs before being included in the study; P: significance<0.05; quasi-naïve: patients who had taken antipsychotics for a period of less than 30 days before being included in the study.

Figures in bold indicate that the difference is statistically significant.

We found statistically significant differences in favour of a greater number of quasi-naïve patients in the following symptoms: in the psychological area, anxiety/laxity/fatigability, somnolence/sedation, increase in the duration of sleep, increased sleeping and emotional indifference; in the neurological area, hypokinesia/akinesia and paresthesias; in the autonomic area, accommodation disorders, increased salivation, polyuria/polydipsia and increased perspiration; and, finally, in the area others, increased sexual desire, decreased sexual desire and tension headaches.

Assessment of involuntary movements

Table 5 shows the baseline results on the MPRC-IMS scale for all the patients who obtained at least a score of slight for the symptoms assessed. The results are presented both considering the entire sample assessed and considering the scores obtained by the 2 groups that constituted the sample (naïve and quasi-naïve patients), controlling the latter by the baseline diagnosis.

Table 5.

Baseline scores for the MPRC-IMS (Maryland Psychiatry Research Center Involuntary Movement Scale).

  Total sampleNo. (%)  Naïve patientsNo. (%)  Quasi-naïve patientsNo. (%)  CMH  P 
Dyskinesia
Spastic tongue movements  95 (35.7)  26 (19.8)  69 (51.1)  21.421  <0.0001 
Kissing/sucking movements, pulling faces  14 (5.4)  5 (3.8)  9 (6.7)  0.968  0.3253 
“Tick-like” movements in the eyes and periorbital region  13 (4.9)  8 (6.1)  5 (3.7)  0.193  0.6606 
Gesticulation (irregular, lateral movements in cheeks and centrofacial region)  21 (7.9)  9 (6.9)  12 (8.9)  0.626  0.4288 
Spastic, irregular movements, with finger extension and flexion  59 (22.2)  59 (22.2)  44 (32.6)  13.751  <0.001 
Habitual shaking of arms and elbows  6 (2.3)  3 (2.3)  3 (2.2)  0.064  0.7998 
Spastic contractions and spastic movements of arms and elbows  44 (16.  13 (9.9)  31 (23.0)  6.015  0.0142 
Spastic movements of neck, shoulders and head, shrugging shoulders  12 (4.5)  7 (5.3)  5 (3.7)  1.163  0.2809 
Alternating knee movements  15 (5.6)  5 (3.8)  10 (7.4)  1.242  0.265 
Spastic movements in ankles, foot tendons and toes  11 (4.1)  6 (4.6)  5 (3.7)  0.162  0.6877 
Exaggerated rocking, arms hanging, hypotonic or flaccid  10 (3.8)  4 (3.1)  6 (4.4)  0.314  0.5754 
Stomping gait  11 (4.1)  2 (1.5)  9 (6.7)  2.019  0.1553 
Rapid forward pelvic projections  1 (0.4)  0 (0)  1 (0.7)  0.824  0.3642 
Involuntary diaphragm movements and/or guttural sounds  3 (1.1)  3 (2.3)  0 (0)  3.836  0.0502 
Parkinsonism
Habitual tongue tremor  30 (11.3)  12 (9.2)  18 (13.3)  0.792  0.3735 
Salivation  3 (1.1)  1 (0.8)  2 (1.5)  2.275  0.1315 
Habitual lip tremor  3 (1.1)  2 (1.5)  1 (0.7)  1.079  0.2989 
Habitual tremor of the eyes and periorbital region  0 (0)  0 (0)  0 (0)  NA  NA 
Loss of eye blinking  7 (2.6)  4 (3.1)  3 (2.2)  0.013  0.9091 
Rigid “mask” facial expression  21 (7.9)  6 (4.6)  15 (11.1)  3.887  0.0487 
Jaw tremor  4 (1.5)  2 (1.5)  2 (1.5)  0.013  0.9106 
“Money-counting” tremor  7 (2.6)  4 (3.1)  3 (2.2)  0.379  0.5384 
Customary resting finger tremor  46 (17.3)  21 (16.0)  25 (18.5)  0.732  0.3921 
Muscle rigidity in arms and elbows  10 (3.8)  5 (3.8)  5 (3.7)  0.287  0.5925 
Muscle rigidity in legs and feet  8 (3.0)  2 (1.5)  6 (4.4)  2.139  0.1436 
Customary leg and foot tremor  2 (0.8)  0 (0)  2 (1.5)  2.532  0.1116 
Decreased rocking with stiff arms  36 (13.5)  9 (6.9  27 (20.0)  6.295  0.0121 
Rigid, foot dragging gait  13 (4.9)  1 (0.8))  12 (8.9)  6.465  0.011 
Assessment
Overall           
Dyskinesia  110 (41.4)  40 (30.5)  70 (51.9)  9.509  0.002 
Parkinsonism  74 (27.8)  24 (18.3)  50 (37.0)  12.498  0.0004 
Akathisia  10 (3.8)  1 (0.8)  9 (6.7)  4.070  0.0437 

CMH: Cochran–Mantel–Haenszel; NA: not applicable; naïve: patients who had not taken any antipsychotic drugs before being included in the study; P: significance<0.05; quasi-naïve: patients who had taken antipsychotics for a period of less than 30 days before being included in the study.

Figures in bold indicate that the difference is statistically significant.

Among the 3 areas assessed, in the case of dyskinesia, statistically significant differences in favour of a greater number of quasi-naïve patients were found in the following symptoms: spasmodic tongue movements, irregular spasmodic movements, with finger extension and flexion, and spasmodic arm and elbow contractions and movements; in parkinsonism, rigid “mask” facial expression, decreased rocking with stiff arms and rigid gait dragging the feet.

In the overall assessments of dyskinesia, parkinsonism and akathisia, a statistically significant greater number of quasi-naïve patients were likewise observed with these symptoms.

Discussion

This article describes the design and baseline results of a study carried out in 4 Spanish hospitals with children and adolescents for which a first or second generation [atypical] antipsychotics was prescribed. We present the follow-up protocol throughout 12 months of treatment, assessing the safety and tolerance of using these drugs in a child–adolescent population. Likewise, we present the assessment tools used.

From the total quasi-naïve patients, 98.4% were prescribed SGA (risperidone, olanzapine, quetiapine or aripiprazole) and only 7 patients were prescribed a FGA (haloperidol, pimozide or chlorpromazine). These data are in keeping with studies on the prevalence of antipsychotics use in children and adolescents, studies that describe the significant increase that has been produced in SGA prescriptions to the detriment of FGA.2From the quasi-naïve patients, only 1.9% were receiving combined antipsychotic treatment; this is a very low percent compared with what normally occurs in the adult population, in which polypharmacy is a general practice (especially in the United States) despite the fact that what is recommended is antipsychotic monotherapy.33–35

Many studies mention the relationship between antipsychotic dose and the appearance of side effects, an aspect also observed regularly in clinical practice. In spite of this, the data that exist up to now provide contradictory results.36–38 Our detailed record-keeping for the drugs, as well as the lengthy 12-month patient follow-up, will make it possible for us to analyse this and to attempt to provide clarifying data.

The patients included in the study had prescriptions for, along with the antipsychotics, other psychotropic drugs (benzodiazepines, antidepressants, mood stabilisers [lithium and antiepileptics] and stimulants); this should be remembered when attributing the appearance of side effects to the action of the antipsychotics or to third-line drugs.39 An example of this is a previous study by our team16 that found a possible protective effect of antidepressants in SGA weight increase.

The areas in which the greatest number of patients presented symptoms when the side effects were analysed using the UKU scale were the psychological, neurological and autonomic areas. A subanalysis differentiating between naïve and quasi-naïve patients revealed a significantly greater number of the latter with these symptoms. In assessing extrapyramidal symptoms, we found similar results, with statistical significance for the greater number of quasi-naïve patients who presented symptoms of dyskinesia, parkinsonism and akathisia. The length of the studies carried out up to now has not been more than 12 weeks40; consequently, this study will also let us see possible changes as well as the development of the extrapyramidal symptoms over longer periods of time. These results obtained at baseline level show that in child–adolescent populations both the appearance of side effects and of extrapyramidal symptoms are already observed from the start of antipsychotic exposure.

Our results should be interpreted bearing in mind a series of limitations. In the first place, the study was carried out in hospital centres, so 72.9% of the sample consisted of patients with hospital admission. This skews the severity of the pathology and includes a bias when attempting to generalise the results obtained with those from other, out-patient samples. In the second place, despite the fact that we measured treatment adherence using objective techniques, this analysis could not be performed in the entire sample because not all of the centres had the techniques available. In the third place, measurements of the severity of the illness were not included; these would have made it possible to assess the efficacy balance between efficacy and side effects. Such measurements should be considered in future studies.

Among the strong points of our study, we can highlight the following: firstly, as far as we know this is the first study with naïve or quasi-naïve children and adolescents, with such a large sample size, in which they have had 12 months of follow-up on antipsychotic treatment, assessing clinical and biological variables to enable early detection of the possible appearance of side effects. Secondly, practically half of the sample consisted of children and adolescents that had never received antipsychotic treatment and the rest had minimal exposure. Thirdly, this study will make it possible to assess directly in child–adolescent populations the safety and tolerance of these drugs. Based on the results obtained in adults, it is impossible to infer their safety and tolerance in individuals still in their growth period; an example of this is the studies showing that the side effects of the SGA are more evident in children than in adults.41–43 In fourth place, one of the interests of clinicians is to establish the differential profile of the antipsychotics. With respect to side effects, the antipsychotics present very heterogeneous profiles, for example, that the weight increase differs from some SGA to others.19 This study will make it possible to provide information on the differential and longitudinal behaviour of the antipsychotics, especially of the SGA. Finally, this study is in agreement with the laws of the FDA (US Food and Drug Administration) and the EMA (European Medicines Agency) – which require studies designed for children and adolescents–that enable the confirmation of the use of these drugs, providing more information on their safety and tolerance in this population.

The main objective of this article was to present a protocol designed to enable early detection of severe side effects from the use of antipsychotic drugs in the child–adolescent population. After the results that are obtained and once their usefulness has been demonstrated, we hope that they facilitate the development and implementation in standard clinical practice of specific follow-up protocols for children and adolescents with antipsychotic treatment.

Ethical disclosuresProtection of people and animals

The authors declare that the procedures followed conformed to the ethical standards of the human experimentation committee in charge and were in agreement with the World Medical Organisation and the Declaration of Helsinki.

Data confidentiality

The authors declare that they followed the protocols of their work centres about the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in this study.

Right to privacy and informed consent

The authors obtained informed consent from the patients and/or subjects included in the article. This document is filed with the corresponding author.

Conflict of interest

The authors have no conflict of interests to declare.

Acknowledgements

We would like to thank the Centre of Biomedical Research in the Mental Health Network (CIBERSAM), Madrid (Spain); for partial funding, the following: the Spanish Ministry of Health, Instituto de Salud Carlos III «Health Research Fund» (F.I.S.-PI04/0455); Madrid Mental Health Association («Miguel Angel Martín» Research Grant); «NARSAD 2005: Independent Investigator Award»; Alicia Koplowitz and Mutua Madrileña foundations; and the Ministries of Science and Innovation, Community of Madrid, Biomedical R&D funding S2010/BMD-2422 AGES (Madrid) for their support.

References
[1]
W.O. Cooper, G.B. Hickson, C. Fuchs, P.G. Arbogast, W.A. Ray.
New users of antipsychotic medications among children enrolled in TennCare.
Arch Pediatr Adolesc Med, 158 (2004), pp. 753-759
[2]
M. Olfson, C. Blanco, L. Liu, C. Moreno, G. Laje.
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry, 63 (2006), pp. 679-685
[3]
A. Zuddas, R. Zanni, T. Usala.
Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
Eur Neuropsychopharmacol, 21 (2011), pp. 600-620
[4]
D. Fraguas, C.U. Correll, J. Merchan-Naranjo, M. Rapado-Castro, M. Parellada, C. Moreno, et al.
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
Eur Neuropsychopharmacol, 21 (2011), pp. 621-645
[5]
D. Fraguas, J. Merchán-Naranjo, C. Arango.
Differential characteristics of the efficacy and tolerability of second-generation antipsychotics in the treatment of psychotic disorders in children and adolescents.
Rev Psiquiatr Salud Ment, 3 (2010), pp. 152-167
[6]
P. Laita, A. Cifuentes, A. Doll, C. Llorente, I. Cortés, M. Parellada, et al.
Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents.
J Child Adolesc Psychopharmacol, 17 (2007), pp. 487-502
[7]
N.C. Patel, M.L. Crismon, K. Hoagwood, M.T. Johnsrud, K.L. Rascati, J.P. Wilson, et al.
Trends in the use of typical and atypical antipsychotics in children and adolescents.
J Am Acad Child Adolesc Psychiatry, 44 (2005), pp. 548-556
[8]
C. Arango, M. Parellada, D.M. Moreno.
Clinical effectiveness of new generation antipsychotics in adolescent patients.
Eur Neuropsychopharmacol, 14 (2004), pp. S471-S479
[9]
R.L. Findling, H. Steiner, E.B. Weller.
Use of antipsychotics in children and adolescents.
J Clin Psychiatry, 66 (2005), pp. 29-40
[10]
B. Vitiello, C. Correll, B. Van Zwieten-Boot, A. Zuddas, M. Parellada, C. Arango.
Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
Eur Neuropsychopharmacol, 19 (2009), pp. 629-635
[11]
P. Pathak, D. West, B.C. Martin, M.E. Helm, C. Henderson.
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001–2005.
Psychiatr Serv, 61 (2010), pp. 123-129
[12]
F. Rani, M.L. Murray, P.J. Byrne, I.C. Wong.
Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom.
Pediatrics, 121 (2008), pp. 1002-1009
[13]
L.J. Kalverdijk, H. Tobi, P.B. Van den Berg, J. Buiskool, L. Wagenaar, R.B. Minderaa, et al.
Use of antipsychotic drugs among Dutch youths between 1997 and 2005.
Psychiatr Serv, 59 (2008), pp. 554-560
[14]
L. Sikich, J.A. Frazier, J. McClellan, R.L. Findling, B. Vitiello, L. Ritz, et al.
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
Am J Psychiatry, 165 (2008), pp. 1420-1431
[15]
C.U. Correll.
Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.
J Am Acad Child Adolesc Psychiatry, 47 (2008), pp. 9-20
[16]
D. Fraguas, J. Merchán-Naranjo, P. Laita, M. Parellada, D. Moreno, A. Ruiz-Sancho, et al.
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
J Clin Psychiatry, 69 (2008), pp. 1166-1175
[17]
P. Tyrer, T. Kendall.
The spurious advance of antipsychotic drug therapy.
[18]
R. Perez-Iglesias, B. Crespo-Facorro, O. Martinez-Garcia, M.L. Ramirez-Bonilla, M. Alvarez-Jimenez, J.M. Pelayo-Teran, et al.
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population.
Schizophr Res, 99 (2008), pp. 13-22
[19]
C. Arango, O. Robles, M. Parellada, D. Fraguas, A. Ruiz-Sancho, O. Medina, et al.
Olanzapine compared to quetiapine in adolescents with a first psychotic episode.
Eur Child Adolesc Psychiatry, 18 (2009), pp. 418-428
[20]
L. Pina, J. Merchán-Naranjo, M.C.A. García-Amador.
Metabolic side effects in antipsychotic-naïve adolescents after 12 months of treatment with second-generation antipsychotics.
Schizophr Bull, 37 (2011), pp. 29
[21]
S.M. Stahl, L. Mignon, J.M. Meyer.
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?.
Acta Psychiatr Scand, 119 (2009), pp. 171-179
[22]
C. Moreno, J. Merchán-Naranjo, M. Álvarez, I. Baeza, J.A. Alda, C. Martínez-Cantarero, et al.
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Bipolar Disord, 12 (2010), pp. 172-184
[23]
C.U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, A.K. Malhotra.
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
JAMA, 302 (2009), pp. 1765-1773
[24]
American Psychiatric Association.
Diagnostic and statistical manual of mental disorders.
4th ed., APA, (1994),
[25]
B. Sobradillo, A. Aguirre, U. Aresti, A. Bilbao, C. Fernández-Ramos, A. Lizárraga, et al.
Curvas y tablas de crecimiento: estudios longitudinal y transversal.
Fundación Faustino Orbegozo Eizaguirre, (2004),
[26]
L. Serra, J. Aranceta, C. Pérez, B. Moreno, R. Tojo, A. Delgado, et al.
Curvas de referencia para la tipificación ponderal.
Criterios para la prevención de la obesidad infantil y juvenil. Documento de consenso del grupo colaborativo AEP-SENC-SEEDO. Dossier de consenso,
[27]
National highblood pressure education Program working group on high blood pressure in children and adolescents.
The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents, 114 (2004), pp. 555-576
[28]
N.C. Andreasen, M. Pressler, P. Nopoulos, D. Miller, B.C. Ho.
Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs.
Biol Psychiatry, 67 (2010), pp. 255-262
[29]
W.A. Marshall, J.M. Tanner.
Variations in pattern of pubertal changes in girls.
Arch Dis Child, 44 (1969), pp. 291-303
[30]
W.A. Marshall, J.M. Tanner.
Variations in the pattern of pubertal changes in boys.
Arch Dis Child, 45 (1970), pp. 13-23
[31]
O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, K. Elgen.
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.
Acta Psychiatr Scand Suppl, 334 (1987), pp. 1-100
[32]
S.L. Cassady, G.K. Thaker, A. Summerfelt, C.A. Tamminga.
The Maryland Psychiatric Research Center scale and the characterization of involuntary movements.
Psychiatry Res, 70 (1997), pp. 21-37
[33]
A.L. Miller, C.S. Craig.
Combination antipsychotics: pros, cons, and questions.
Schizophr Bull, 28 (2002), pp. 105-109
[34]
S.M. Stahl, M.M. Grady.
A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
Curr Med Chem, 11 (2004), pp. 313-327
[35]
T.A. Moore, R.W. Buchanan, P.F. Buckley, J.A. Chiles, R.R. Conley, M.L. Crismon, et al.
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.
J Clin Psychiatry, 68 (2007), pp. 1751-1762
[36]
V. Simon, R. Van Winkel, M. De Hert.
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
J Clin Psychiatry, 70 (2009), pp. 1041-1050
[37]
C.L. Alfaro, M. Wudarsky, R. Nicolson, P. Gochman, A. Sporn, M. Lenane, et al.
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
J Child Adolesc Psychopharmacol, 12 (2002), pp. 83-91
[38]
M. Haas, A.S. Unis, J. Armenteros, M.D. Copenhaver, J.A. Quiroz, S.F. Kushner.
A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
J Child Adolesc Psychopharmacol, 19 (2009), pp. 611-621
[39]
G. Goodwin, W. Fleischhacker, C. Arango, P. Baumann, M. Davidson, M. De Hert, et al.
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Eur Neuropsychopharmacol, 19 (2009), pp. 520-532
[40]
J.B. Jensen, S. Kumra, W. Leitten, J. Oberstar, A. Anjum, T. White, et al.
A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
J Child Adolesc Psychopharmacol, 18 (2008), pp. 317-326
[41]
C.U. Correll, H.E. Carlson.
Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents.
J Am Acad Child Adolesc Psychiatry, 45 (2006), pp. 771-791
[42]
C.U. Correll, E.M. Sheridan, M.P. DelBello.
Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials.
Bipolar Disord, 12 (2010), pp. 116-141
[43]
M.P. DelBello, C.U. Correll.
Primum non nocere: balancing the risks and benefits of prescribing psychotropic medications for youth with bipolar disorder.
Bipolar Disord, 12 (2010), pp. 113-115

Please cite this article as: Merchán-Naranjo J, et al. Efectos secundarios del tratamiento antipsicótico en niños y adolescentes naïve o quasi-naïve: diseño de un protocolo de seguimiento y resultados basales. Rev Psiquiatr Salud Ment (Barc.). 2012;5:217–28.

Copyright © 2011. SEP y SEPB
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos